Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)

被引:70
作者
Just, Katja Susanne [1 ]
Steffens, Michael [1 ]
Swen, Jesse Joachim [2 ]
Patrinos, George P. [3 ]
Guchelaar, Henk-Jan [2 ]
Stingl, Julia Carolin [1 ,4 ]
机构
[1] Univ Bonn, Sch Med, Div Res, Fed Inst Drugs & Med Devices, Kurt Georg Kiesinger Allee 3, D-53175 Bonn, Germany
[2] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Leiden, Netherlands
[3] Univ Patras, Sch Hlth Sci, Dept Pharm, Patras, Greece
[4] Univ Bonn, Fac Med, Ctr Translat Med, Bonn, Germany
基金
欧盟地平线“2020”;
关键词
Pharmacogenomics; Pharmacogenetics; Clinical pharmacology; Cultural diversity; Medical education; ADVERSE DRUG-REACTIONS; PERSONALIZED MEDICINE; CHALLENGES; PROGRAM; BARRIERS; SCIENCE; TESTS;
D O I
10.1007/s00228-017-2292-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Due to the diversity within Europe, the implementation of pharmacogenomic testing in clinical practice faces specific challenges. In the context of the European pharmacogenomics implementation project "Ubiquitous Pharmacogenomics" (U-PGx; funded by the European Commission), we studied the current educational background. We developed a questionnaire including 29 questions. It was spread out to healthcare professionals working at the future implementation sites (in Austria, Greece, Italy, Netherlands, Slovenia, Spain and Great Britain) of the U-PGx project in preparation of an educational programme. Aim of the survey was to analyse the current educational situation at the implementation sites. In total, 70 healthcare professionals participated in the survey. Of participants, 84.3% found pharmacogenomics relevant to their current practice, but experience was still rare. More than two-thirds (65.7%) did not order nor recommend a pharmacogenomic test in the past year. This was mainly attributed to not having enough knowledge on pharmacogenomics (40.0%). Needs were identified in application of pharmacogenomics (identifying drugs 41.4%, interpreting test results 37.2%) as well as in underlining mechanisms (better knowledge on drug metabolism 67.1%, better knowledge on basic principles of pharmacogenomics 60.0%). This study analysed the specific attitudes, experience and education on pharmacogenomics of future users. There was a general positive attitude and interest towards pharmacogenomic testing. However, the grade of own experience, and knowledge about application and interpretation of pharmacogenomics caused uncertainty. Thus, education and training programmes may be helpful for implementation of pharmacogenomics at a homogenous level within Europe.
引用
收藏
页码:1247 / 1252
页数:6
相关论文
共 30 条
[1]  
Bank PCD., 2018, Pharmacogenomics
[2]   Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers [J].
Dunnenberger, Henry M. ;
Crews, Kristine R. ;
Hoffman, James M. ;
Caudle, Kelly E. ;
Broeckel, Ulrich ;
Howard, Scott C. ;
Hunkler, Robert J. ;
Klein, Teri E. ;
Evans, William E. ;
Relling, Mary V. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55, 2015, 55 :89-+
[3]   Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].
Evans, WE ;
McLeod, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549
[4]   Development and Evaluation of a Pharmacogenomics Educational Program for Pharmacists [J].
Formea, Christine M. ;
Nicholson, Wayne T. ;
McCullough, Kristen B. ;
Berg, Kevin D. ;
Berg, Melody L. ;
Cunningham, Julie L. ;
Merten, Julianna A. ;
Ou, Narith N. ;
Stollings, Joanna L. .
AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 2013, 77 (01)
[5]   Pharmacogenetics in Europe: Barriers and Opportunities [J].
Gurwitz, D. ;
Zika, E. ;
Hopkins, M. M. ;
Gaisser, S. ;
Ibarreta, D. .
PUBLIC HEALTH GENOMICS, 2009, 12 (03) :134-141
[6]   Educating health-care professionals about genetics and genomics [J].
Guttmacher, Alan E. ;
Porteous, Mary E. ;
McInerney, Joseph D. .
NATURE REVIEWS GENETICS, 2007, 8 (02) :151-U6
[7]   Primary care physicians' knowledge of and experience with pharmacogenetic testing [J].
Haga, S. B. ;
Burke, W. ;
Ginsburg, G. S. ;
Mills, R. ;
Agans, R. .
CLINICAL GENETICS, 2012, 82 (04) :388-394
[8]   An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe [J].
Horgan, Denis ;
Jansen, Marleen ;
Leyens, Lada ;
Lal, Jonathan A. ;
Sudbrak, Ralf ;
Hackenitz, Erica ;
Busshoff, Ulrike ;
Ballensiefen, Wolfgang ;
Brand, Angela .
PUBLIC HEALTH GENOMICS, 2014, 17 (5-6) :287-298
[9]   Role of pharmacogenetics in public health and clinical health care: a SWOT analysis [J].
Kapoor, Ritika ;
Tan-Koi, Wei Chuen ;
Teo, Yik-Ying .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2016, 24 (12) :1651-1657
[10]   Prevalence, Characteristics, and Publication of Discontinued Randomized Trials [J].
Kasenda, Benjamin ;
von Elm, Erik ;
You, John ;
Bluemle, Anette ;
Tomonaga, Yuki ;
Saccilotto, Ramon ;
Amstutz, Alain ;
Bengough, Theresa ;
Meerpohl, Joerg J. ;
Stegert, Mihaela ;
Tikkinen, Kari A. O. ;
Neumann, Ignacio ;
Carrasco-Labra, Alonso ;
Faulhaber, Markus ;
Mulla, Sohail M. ;
Mertz, Dominik ;
Akl, Elie A. ;
Bassler, Dirk ;
Busse, Jason W. ;
Ferreira-Gonzalez, Ignacio ;
Lamontagne, Francois ;
Nordmann, Alain ;
Gloy, Viktoria ;
Raatz, Heike ;
Moja, Lorenzo ;
Rosenthal, Rachel ;
Ebrahim, Shanil ;
Schandelmaier, Stefan ;
Xin, Sun ;
Vandvik, Per O. ;
Johnston, Bradley C. ;
Walter, Martin A. ;
Burnand, Bernard ;
Schwenkglenks, Matthias ;
Hemkens, Lars G. ;
Bucher, Heiner C. ;
Guyatt, Gordon H. ;
Briel, Matthias .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (10) :1045-1051